Since 2014, this 1-thio-d-glucitol 290 has been known as luseogliflozin, and it is an orally active SGLT2 inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus [75]. This evidence concerns the gene SLC5A2 and diabetes mellitus.